Table 1.
Comparison of baseline characteristics between different ranibizumab treatment regimens for nAMD
| MARINA3 | ANCHOR4 | CATT12 | TER17 | Observe and plan* | |
|---|---|---|---|---|---|
| Gender (% female) | 63.3 | 46.4 | 61.9 | 66.3 | 63.5 |
| Race (% Caucasian) | 96.7 | 97.1 | 98.6 | 100 | 100 |
| Age (mean±SD) | 77±8.0 | 76±8.6 | 79.3±7.8 | 80.6±6.6 | 79.5±7.8 |
| VA mean (median) | na | na | 20/60+1 | 20/135 (20/100) | 20/80+3 (20/60+3) |
| VA≤20/200 (%) | 12.9 | 23.0 | 6.8 | 22.8 | 11.3 |
| 20/200<VA<20/40 | 72.1 | 72.7 | 62.3 | 67.4 | 58.3 |
| VA≥20/40 | 15.0 | 4.3 | 30.9 | 9.8 | 30.4 |
| Predominately classic CNV lesion (%) | 0 | 96.4 | na | 19.6 | 24.4 |
| Minimally classic CNV lesion (%) | 37.9 | 3.6 | na | 28.7 | 10.4 |
| Occult with no classic CNV (%) | 62.1 | 0 | na | 52.5 | 45.2 |
| Retinal angiomatous proliferation (%) | na | na | na | na | 20.0 |
| Size of lesion (disc areas) | 4.5 | 1.79 | 2.7 | 2.6 | 2.48 |
*Treatment regimen of this study.
CNV, choroidal neovascularisation; na, not applicable; nAMD; neovascular age-related macular degeneration; TER, treat and extend regimen; VA, visual acuity.